News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
815,506 Results
Type
Article (74329)
Company Profile (644)
Press Release (740533)
Multimedia
Podcasts (121)
Webinars (13)
Section
Business (227497)
Career Advice (3718)
Deals (39303)
Drug Delivery (129)
Drug Development (89356)
Employer Resources (198)
FDA (17844)
Job Trends (17129)
News (387782)
Policy (38765)
Tag
2024 BioCapital Digital (20)
2024 BioForest Digital (16)
2024 BioForest Standard (1)
2024 BioMidwest Digital (14)
2024 BioMidwest Standard (2)
2024 Bio NC Digital (19)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (20)
2024 Biotech Beach Digital (15)
2024 Biotech Beach Standard (9)
2024 Genetown Digital (10)
2024 Genetown Standard (11)
2024 Lone Star Bio Digital (17)
2024 Pharm Country Digital (13)
2024 Pharm Country Standard (6)
2025 BioForest Digital (6)
2025 Lone Star Bio Digital (10)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (2)
Academia (2998)
Academic (1)
Accelerated approval (6)
Adcomms (29)
Allergies (90)
Alliances (55953)
ALS (97)
Alzheimer's disease (1490)
Antibody-drug conjugate (ADC) (144)
Approvals (17808)
Artificial intelligence (286)
Autoimmune disease (27)
Automation (15)
Bankruptcy (403)
Best Places to Work (12633)
BIOSECURE Act (21)
Biosimilars (118)
Biotechnology (440)
Bladder cancer (67)
Brain cancer (31)
Breast cancer (284)
Cancer (2246)
Cardiovascular disease (195)
Career advice (3165)
Career pathing (33)
CAR-T (164)
Cell therapy (457)
Cervical cancer (21)
Clinical research (72053)
Collaboration (869)
Compensation (526)
Complete response letters (30)
COVID-19 (2859)
CRISPR (45)
C-suite (245)
Cystic fibrosis (107)
Data (2107)
Decentralized trials (2)
Denatured (41)
Depression (51)
Diabetes (283)
Diagnostics (6894)
Digital health (19)
Diversity (9)
Diversity, equity & inclusion (48)
Drug discovery (129)
Drug pricing (123)
Drug shortages (33)
Duchenne muscular dystrophy (99)
Earnings (93610)
Editorial (43)
Employer branding (25)
Employer resources (167)
Events (128338)
Executive appointments (738)
FDA (19095)
Featured Employer (64)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (776)
Gene editing (115)
Generative AI (28)
Gene therapy (336)
GLP-1 (839)
Government (5097)
Grass and pollen (5)
Guidances (51)
Healthcare (20866)
Huntington's disease (25)
IgA nephropathy (28)
Immunology and inflammation (139)
Indications (27)
Infectious disease (3017)
Inflammatory bowel disease (149)
Inflation Reduction Act (11)
Influenza (55)
Intellectual property (95)
Interviews (726)
IPO (17731)
IRA (51)
Job creations (4989)
Job search strategy (2593)
Kidney cancer (10)
Labor market (40)
Layoffs (545)
Leadership (21)
Legal (9911)
Liver cancer (78)
Lung cancer (326)
Lymphoma (144)
Machine learning (5)
Management (65)
Manufacturing (320)
MASH (70)
Medical device (14584)
Medtech (14589)
Mergers & acquisitions (22084)
Metabolic disorders (757)
Multiple sclerosis (82)
NASH (23)
Neurodegenerative disease (107)
Neuropsychiatric disorders (31)
Neuroscience (2060)
NextGen: Class of 2025 (7635)
Non-profit (5075)
Northern California (2600)
Now hiring (39)
Obesity (413)
Opinion (272)
Ovarian cancer (76)
Pain (92)
Pancreatic cancer (83)
Parkinson's disease (157)
Partnered (22)
Patents (239)
Patient recruitment (103)
Peanut (51)
People (64003)
Pharmaceutical (133)
Pharmacy benefit managers (21)
Phase I (22267)
Phase II (31420)
Phase III (23704)
Pipeline (1165)
Policy (161)
Postmarket research (3256)
Preclinical (9780)
Press Release (72)
Prostate cancer (103)
Psychedelics (38)
Radiopharmaceuticals (267)
Rare diseases (420)
Real estate (7146)
Recruiting (75)
Regulatory (25991)
Reports (57)
Research institute (2654)
Resumes & cover letters (579)
Rett syndrome (4)
RNA editing (4)
RSV (50)
Schizophrenia (77)
Series A (137)
Series B (87)
Service/supplier (26)
Sickle cell disease (58)
Southern California (2255)
Special edition (18)
Spinal muscular atrophy (165)
Sponsored (33)
Startups (4195)
State (2)
Stomach cancer (16)
Supply chain (72)
Tariffs (29)
The Weekly (78)
United States (23510)
Vaccines (790)
Venture capitalists (41)
Weight loss (299)
Women's health (37)
Worklife (19)
Date
Today (11)
Last 7 days (511)
Last 30 days (2499)
Last 365 days (35435)
2025 (9949)
2024 (37898)
2023 (42567)
2022 (53926)
2021 (58723)
2020 (57663)
2019 (51302)
2018 (39084)
2017 (36831)
2016 (37746)
2015 (43733)
2014 (38432)
2013 (34406)
2012 (36296)
2011 (36418)
2010 (35844)
Location
Africa (1191)
Alabama (59)
Alaska (7)
Arizona (245)
Arkansas (14)
Asia (48555)
Australia (8355)
California (6067)
Canada (1983)
China (525)
Colorado (271)
Connecticut (288)
Delaware (144)
Europe (109655)
Florida (889)
Georgia (216)
Hawaii (1)
Idaho (63)
Illinois (590)
India (29)
Indiana (324)
Iowa (10)
Japan (154)
Kansas (108)
Kentucky (27)
Louisiana (13)
Maine (70)
Maryland (930)
Massachusetts (4688)
Michigan (240)
Minnesota (406)
Mississippi (2)
Missouri (88)
Montana (31)
Nebraska (26)
Nevada (62)
New Hampshire (68)
New Jersey (1748)
New Mexico (31)
New York (1725)
North Carolina (1088)
North Dakota (8)
Northern California (2600)
Ohio (209)
Oklahoma (15)
Oregon (45)
Pennsylvania (1347)
Puerto Rico (12)
Rhode Island (33)
South America (1564)
South Carolina (21)
South Dakota (1)
Southern California (2255)
Tennessee (102)
Texas (910)
Utah (182)
Virginia (158)
Washington D.C. (67)
Washington State (578)
West Virginia (3)
Wisconsin (63)
815,506 Results for "chugai formerly chugai pharmaceutical co ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Araris Biotech AG Announces Research Collaboration and Option to License Agreement with Chugai Pharmaceutical Co. to Develop Next-Generation ADCs Using Araris’ AraLinQ™ technology
January 8, 2025
·
2 min read
Press Releases
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
March 25, 2025
·
5 min read
Chugai and Biofourmis Enter into New Partnership Focused on Data-Driven Virtual Care for Endometriosis-Related Pain
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) and Biofourmis, a global leader in technology-enabled care delivery, announced that they have entered into a new partnership agreement for the continued development and real-world use of digital solutions to objectively measure pain in patients with endometriosis.
March 2, 2023
·
6 min read
Press Releases
WORK Medical Technology Group LTD Announces Strategic Partnership with Shanghai Chartwell Medical Device Co., Ltd.
March 3, 2025
·
5 min read
Drug Development
Alebund Reports Update for AP306 (EOS789), a First-in-Class Pan-inhibitor of Sodium-dependent Phosphate Transporters, from a Completed Phase II Clinical Trial in Patients with Hyperphosphatemia on Hemodialysis
Alebund Pharmaceuticals (“Alebund” or the “Company”) announced phase II proof-of-concept study results for the investigational drug, AP306, a first-in-class, pan-inhibitor of sodium-dependent phosphate transporters, which was discovered by Chugai Pharmaceutical Co., Ltd., and previously referred by EOS789.
December 13, 2023
·
4 min read
Press Releases
BioCity Biopharmaceutics Co., Ltd. Announces Clinical Collaboration to Evaluate BC3195 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors
March 13, 2025
·
3 min read
Business
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
Verrica Pharmaceuticals Inc. today announced that it has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. Ltd. (Torii), to jointly conduct a global pivotal Phase 3 clinical trial of YCANTH® for the treatment of common warts.
May 15, 2024
·
9 min read
Business
Halozyme Therapeutics, Inc. and Chugai Pharmaceutical Enter Global Collaboration and License Agreement for ENHANZE® Technology
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a global collaboration and license agreement with Chugai Pharmaceutical Co., Ltd. that gives exclusive access to Halozyme’s ENHANZE® drug delivery technology, recombinant human hyaluronidase PH20 enzyme (rHuPH20), for an undisclosed target.
March 24, 2022
·
5 min read
Press Releases
Lakeside Holding Enters Medical Logistics Sector with Acquisition of Hupan Pharmaceutical (Hubei) Co., Ltd.
November 11, 2024
·
4 min read
New Four-year Data Show Sustained Relapse Reduction by Chugai’s Enspryng in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Chugai Pharmaceutical Co., Ltd. announced new longer-term efficacy and safety data for Enspryng® [generic name: satralizumab ], a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody created by Chugai.
October 14, 2021
·
6 min read
1 of 81,551
Next
